Contrafect Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

About Contrafect Contact Number

Contact Us. 28 Wells Ave. Yonkers, NY 10701. (914) 207-2300. View. View available positions at Contrafect and grow your career! Learn More ». About. We are focused on developing first-in-class biologic therapies for life-threatening, drug-resistant infectious diseases.

Contact US: https://www.contrafect.com/contact-us

Transfer

36 People Used

See More ››

Contacts :: ContraFect Corporation (CFRX)

Michael Messinger T: 914-207-2300 [email protected]contrafect.com. Transfer Agent. American Stock Transfer

View Contact ››

ContraFect

30 People Used

See More ››

ContraFect Corporation (CFRX)

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year …

View Contact ››

Address

37 People Used

See More ››

Profile :: ContraFect Corporation (CFRX)

Address: 28 Wells Avenue 3rd Floor Yonkers, NY 10701 US. Telephone: 914-207-2300. Email: [email protected]contrafect.com

View Contact ››

Monoclonal

55 People Used

See More ››

ContraFect

Phone Number 9142072300. ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses.

View Contact ››

Cassino

57 People Used

See More ››

Management Team :: ContraFect Corporation (CFRX)

Cara Cassino, M.D. Chief Medical Officer and Executive Vice President of Research and Development Cara Cassino, M.D. View Bio

View Contact ››

Careers

41 People Used

See More ››

Careers :: ContraFect Corporation (CFRX)

Careers. ContraFect Corporation, a vibrant and growing biotech company in Westchester County, NY, just outside of New York City, is building its scientific team to develop anti-infective therapies using direct lytic agents, or DLAs, to treat life-threatening, drug-resistant infectious diseases.

View Contact ››

Therapy

43 People Used

See More ››

Product Pipeline :: ContraFect Corporation (CFRX)

We believe CF-370 represents the first lysin to bypass the outer membrane of P. aeruginosa and to enable potent activity in human serum. We have also developed a novel, engineered variant of exebacase, CF-296, with potential as a targeted therapy for deep-seated, invasive biofilm-associated Staph aureus infections such as prosthetic joint

View Contact ››

ContraFect

161 People Used

See More ››

ContraFect Corp LinkedIn

ContraFect Corp

View Contact ››

Patent

50 People Used

See More ››

Press Releases :: ContraFect Corporation (CFRX)

ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office. May 3, 2021.

View Contact ››

Whether

118 People Used

See More ››

Press Releases :: ContraFect Corporation (CFRX)

Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contact Barbara Ryan Clermont Partners Tel: 203-274-2825

View Contact ››

Please leave your comments here:

Popular Brands

Cerner
Cae
Crh
Costco